
Australia’s antitrust regulator announced on Tuesday, January 4, it has contacted suppliers of COVID-19 rapid antigen test kits to examine pricing pressures in the market, as calls grow louder for the government to make the tests free amid a severe shortage of the kits, reported Reuters.
The Australian Competition and Consumer Commission (ACCC) stated it will review information received from suppliers, retailers, and the public to determine any potential misconduct.
Australia approved more than a dozen rapid antigen test kits and a majority of them are from China.
Hangzhou Biotest Biotech, whose rapid antigen test was approved in Australia in October, stated orders for its product from the country increased significantly in December and the trend continued in early January.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Belgian Authorities Detain Multiple Individuals Over Alleged Huawei Bribery in EU Parliament
Mar 13, 2025 by
CPI
Grubhub’s Antitrust Case to Proceed in Federal Court, Second Circuit Rules
Mar 13, 2025 by
CPI
Pharma Giants Mallinckrodt and Endo to Merge in Multi-Billion-Dollar Deal
Mar 13, 2025 by
CPI
FTC Targets Meta’s Market Power, Calls Zuckerberg to Testify
Mar 13, 2025 by
CPI
French Watchdog Approves Carrefour’s Expansion, Orders Store Sell-Off
Mar 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li